TU Munich | Date: 2016-11-28
A method is provided for demodulation of an analog receive signal carrying information, wherein a number of more than two analog signals is formed from the receive signal in separate channels such that the receive signal is multiplied in each case by a period function, the phase thereof respectively differing in the channels, and wherein the multiple signals are each low-pass filtered.
TU Munich | Date: 2015-06-22
Contacting apparatus for contacting an energy storage cell (1) comprising at least one printed circuit board (5) which is provided for discharging the electrical energy stored in the energy storage cell (1), wherein at least one electric pole of the energy storage cell (1) is pressed by a releasable mechanical connection (7) with a specific contact pressing force against an electrically conductive layer (5c) of the at least one printed circuit board (5) which is located on a front side of the at least one printed circuit board (5) facing the energy storage cell (1).
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: SC1-PM-01-2016 | Award Amount: 15.04M | Year: 2017
The complex interactions between genetic and non-genetic factors produce heterogeneities in patients as reflected in the diversity of pathophysiology, clinical manifestations, response to therapies, disease development and progression. Yet, the full potential of personalized medicine entails biomarker-guided delivery of efficient therapies in stratified patient populations. MultipleMS will therefore develop, validate, and exploit methods for patient stratification in Multiple Sclerosis, a chronic inflammatory disease and a leading causes of non-traumatic disability in young adults, with an estimated cost of 37 000 per patient per year over a duration of 30 years. Here we benefit from several large clinical cohorts with multiple data types, including genetic and lifestyle information. This in combination with publically available multi-omics maps enables us to identify biomarkers of the clinical course and the response to existing therapies in a real-world setting, and to gain in-depth knowledge of distinct pathogenic pathways setting the stage for development of new interventions. To create strategic global synergies, MultipleMS includes 21 partners and covers not only the necessary clinical, biological, and computational expertise, but also includes six industry partners ensuring dissemination and exploitation of the methods and clinical decision support system. Moreover, the pharmaceutical industry partners provide expertise to ensure optimal selection and validation of clinically relevant biomarkers and new targets. Our conceptual personalized approach can readily be adapted to other immune-mediated diseases with a complex gene-lifestyle background and broad clinical spectrum with heterogeneity in treatment response. MultipleMS therefore goes significantly beyond current state-of-the-art thereby broadly affecting European policies, healthcare systems, innovation in translating big data and basic research into evidence-based personalized clinical applications.
Agency: European Commission | Branch: H2020 | Program: SGA-RIA | Phase: FETFLAGSHIP | Award Amount: 89.00M | Year: 2016
This project is the second in the series of EC-financed parts of the Graphene Flagship. The Graphene Flagship is a 10 year research and innovation endeavour with a total project cost of 1,000,000,000 euros, funded jointly by the European Commission and member states and associated countries. The first part of the Flagship was a 30-month Collaborative Project, Coordination and Support Action (CP-CSA) under the 7th framework program (2013-2016), while this and the following parts are implemented as Core Projects under the Horizon 2020 framework. The mission of the Graphene Flagship is to take graphene and related layered materials from a state of raw potential to a point where they can revolutionise multiple industries. This will bring a new dimension to future technology a faster, thinner, stronger, flexible, and broadband revolution. Our program will put Europe firmly at the heart of the process, with a manifold return on the EU investment, both in terms of technological innovation and economic growth. To realise this vision, we have brought together a larger European consortium with about 150 partners in 23 countries. The partners represent academia, research institutes and industries, which work closely together in 15 technical work packages and five supporting work packages covering the entire value chain from materials to components and systems. As time progresses, the centre of gravity of the Flagship moves towards applications, which is reflected in the increasing importance of the higher - system - levels of the value chain. In this first core project the main focus is on components and initial system level tasks. The first core project is divided into 4 divisions, which in turn comprise 3 to 5 work packages on related topics. A fifth, external division acts as a link to the parts of the Flagship that are funded by the member states and associated countries, or by other funding sources. This creates a collaborative framework for the entire Flagship.
Lang K.,Medical Research Council Laboratory of Molecular Biology |
Chin J.W.,TU Munich
Chemical Reviews | Year: 2014
A range of chemoselective reactions have been used to label isolated biomolecules, cell surface biomolecules, and intracellular biomolecules at physiological temperatures and pressures. Many of these reactions proceed under aqueous conditions and produce nontoxic or no byproducts. The rates of these chemoselective reactions span 9 orders of magnitude and the recent development of rapid reactions promises applications of labeling to previously inaccessible biological problems. The development of reactions that are chemoselective and rapid under biologically relevant conditions is being rapidly translated into approaches for selective protein labeling in cells and animals via genetic code expansion. Although genetic code expansion approaches commonly direct unnatural amino acid incorporation in response to the amber codon, there appears to be minimal background labeling resulting from incorporation and labeling at endogenous amber codons in E. coli.